Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Nick Thatcher, Kevin Carroll, Sumitra Thongprasert et al.|The Lancet|2005Cited by 2.1k
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung CancerFred R. Hirsch, Brian R. Holloway, Marileila Varella‐Garcia et al.|Journal of Clinical Oncology|2006Cited by 702
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung CancerGiorgio V. Scagliotti, Nasser H. Hanna, Silvia Novello et al.|Journal of Clinical Oncology|2010Cited by 454